Literature DB >> 17981072

Low and high affinity receptors mediate cellular uptake of heparanase.

Olga Ben-Zaken1, Itay Shafat, Svetlana Gingis-Velitski, Haim Bangio, Idil Kasuto Kelson, Tal Alergand, Yehudit Amor, Ruth Ben-Yakar Maya, Israel Vlodavsky, Neta Ilan.   

Abstract

Heparanase is an endoglycosidase which cleaves heparan sulfate and hence participates in degradation and remodeling of the extracellular matrix. Importantly, heparanase activity correlated with the metastatic potential of tumor-derived cells, attributed to enhanced cell dissemination as a consequence of heparan sulfate cleavage and remodeling of the extracellular matrix barrier. Heparanase has been characterized as a glycoprotein, yet glycan biochemical analysis was not performed to date. Here, we applied the Qproteometrade mark GlycoArray kit to perform glycan analysis of heparanase, and compared the kit results with the more commonly used biochemical analyses. We employed fibroblasts isolated from patients with I-cell disease (mucolipidosis II), fibroblasts deficient of low density lipoprotein receptor-related protein and fibroblasts lacking mannose 6-phosphate receptor, to explore the role of mannose 6-phosphate in heparanase uptake. Iodinated heparanase has been utilized to calculate binding affinity. We provide evidence for hierarchy of binding to cellular receptors as a function of heparanase concentration. We report the existence of a high affinity, low abundant (i.e., low density lipoprotein receptor-related protein, mannose 6-phosphate receptor), as well as a low affinity, high abundant (i.e., heparan sulfate proteoglycan) receptors that mediate heparanase binding, and suggest that these receptors co-operate to establish high affinity binding sites for heparanase, thus maintaining extracellular retention of the enzyme tightly regulated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981072      PMCID: PMC2358949          DOI: 10.1016/j.biocel.2007.09.003

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  44 in total

Review 1.  Mannose 6-phosphate receptors: new twists in the tale.

Authors:  Pradipta Ghosh; Nancy M Dahms; Stuart Kornfeld
Journal:  Nat Rev Mol Cell Biol       Date:  2003-03       Impact factor: 94.444

Review 2.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development.

Authors:  D M Ornitz
Journal:  Bioessays       Date:  2000-02       Impact factor: 4.345

3.  Heterodimer formation is essential for heparanase enzymatic activity.

Authors:  Flonia Levy-Adam; Hua-Quan Miao; Robert L Heinrikson; Israel Vlodavsky; Neta Ilan
Journal:  Biochem Biophys Res Commun       Date:  2003-09-05       Impact factor: 3.575

4.  Processing and activation of latent heparanase occurs in lysosomes.

Authors:  Anna Zetser; Flonia Levy-Adam; Victoria Kaplan; Svetlana Gingis-Velitski; Yulia Bashenko; Shay Schubert; Moshe Y Flugelman; Israel Vlodavsky; Neta Ilan
Journal:  J Cell Sci       Date:  2004-05-01       Impact factor: 5.285

5.  LDL receptor-related protein as a component of the midkine receptor.

Authors:  H Muramatsu; K Zou; N Sakaguchi; S Ikematsu; S Sakuma; T Muramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

Review 6.  The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation.

Authors:  Vito Ferro; Edward Hammond; Jon K Fairweather
Journal:  Mini Rev Med Chem       Date:  2004-08       Impact factor: 3.862

7.  Secretion of heparanase protein is regulated by glycosylation in human tumor cell lines.

Authors:  Siro Simizu; Keisuke Ishida; Michal K Wierzba; Hiroyuki Osada
Journal:  J Biol Chem       Date:  2003-10-22       Impact factor: 5.157

8.  Heparanase affects adhesive and tumorigenic potential of human glioma cells.

Authors:  Anna Zetser; Yulia Bashenko; Hua-Quan Miao; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

9.  Heparanase induces endothelial cell migration via protein kinase B/Akt activation.

Authors:  Svetlana Gingis-Velitski; Anna Zetser; Moshe Y Flugelman; Israel Vlodavsky; Neta Ilan
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

10.  Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts.

Authors:  Liat Nadav; Amiram Eldor; Oron Yacoby-Zeevi; Eli Zamir; Iris Pecker; Neta Ilan; Benjamin Geiger; Israel Vlodavsky; Ben-Zion Katz
Journal:  J Cell Sci       Date:  2002-05-15       Impact factor: 5.285

View more
  12 in total

1.  High glucose facilitated endothelial heparanase transfer to the cardiomyocyte modifies its cell death signature.

Authors:  Fulong Wang; Jocelyn Jia; Nathaniel Lal; Dahai Zhang; Amy Pei-Ling Chiu; Andrea Wan; Israel Vlodavsky; Bahira Hussein; Brian Rodrigues
Journal:  Cardiovasc Res       Date:  2016-12       Impact factor: 10.787

2.  Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity.

Authors:  Flonia Levy-Adam; Sari Feld; Victoria Cohen-Kaplan; Anna Shteingauz; Miriam Gross; Gil Arvatz; Inna Naroditsky; Neta Ilan; Ilana Doweck; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

3.  Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis.

Authors:  Menachem Bitan; Lola Weiss; Israel Reibstein; Michael Zeira; Yakov Fellig; Shimon Slavin; Eyal Zcharia; Arnon Nagler; Israel Vlodavsky
Journal:  Mol Immunol       Date:  2010-06       Impact factor: 4.407

Review 4.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

5.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

6.  Clinical significance of urine heparanase in bladder cancer progression.

Authors:  Itay Shafat; Dov Pode; Tamar Peretz; Neta Ilan; Israel Vlodavsky; Benjamin Nisman
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

7.  Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation.

Authors:  Menachem Bitan; Lola Weiss; Michael Zeira; Eyal Zcharia; Shimon Slavin; Arnon Nagler; Israel Vlodavsky
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

Review 8.  Heparanase: busy at the cell surface.

Authors:  Liat Fux; Neta Ilan; Ralph D Sanderson; Israel Vlodavsky
Journal:  Trends Biochem Sci       Date:  2009-09-03       Impact factor: 13.807

9.  Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling.

Authors:  Liat Fux; Nir Feibish; Victoria Cohen-Kaplan; Svetlana Gingis-Velitski; Sari Feld; Chen Geffen; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

Review 10.  Biology of the Heparanase-Heparan Sulfate Axis and Its Role in Disease Pathogenesis.

Authors:  Israel Vlodavsky; Uri Barash; Hien M Nguyen; Shi-Ming Yang; Neta Ilan
Journal:  Semin Thromb Hemost       Date:  2021-04-01       Impact factor: 6.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.